glp 1 medication reviews Clinical review of how glucagon-like peptide-1 agonist obesity medications decrease sexual desire, and a biopsychosocial model for why we don't 'see' it SSAT Complex GS Fellowship Virtual

doi: 10.1002/14651858.CD011031.pub3 13 BonavinaGTaylorHS

There is also emerging evidence suggesting its benefits in preventing severe cases of COVID-19 and long COVID

In April 2026, The Foundation for Prader-Willi Research (FPWR) announced a venture philanthropy investment in ConSynance Therapeutics to support the advancement of CSTI-500, ConSynance s investigational therapy for the treatment of behavioral dysregulation and hyperphagia in PWS

Effects of Exercise on Irisin, BDNF and IL-6 Serum Levels in Patients with Progressive Multiple Sclerosis

Short-Term (3-6 months) Great for jumpstarting weight loss, improving insulin sensitivity, and building new habits